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The discovery and introduction of therapy with biologic DMARDs, or 'biologics' , represents one of the most crucial advances in the field of rheumatology. For patients with rheumatoid arthritis (RA), biologics have transformed what was, for many, an incurable and devastating disease into a disease that can be fully controlled 1 . Although multiple randomized clinical trials (RCTs) have demonstrated the efficacy of these therapies, the nature of RCT recruitment and short follow-up periods mean that efficacy (how a therapy performs under clinical trial conditions) might not directly translate into effectiveness (how a therapy performs under standard clinical practice conditions). A number of biologics registers have therefore been established within the rheumatology community so that additional data from 'real-world' practice can be captured and this evidence gap bridged. In this Perspectives article, we discuss the unique features, differences in methodological approaches and challenges underlying diagnoses and start and stop dates for therapies, as well as treatment outcomes. These outcomes might include disease activity, patient reported outcome measures (such as the Health Assessment Questionnaire) or the occurrence of new comorbidities or adverse events. Although the majority of registers capture data across all these areas, each register differs in design. For example, the UK 3 and Germany 4 established bespoke new cohort studies that recruited patients at the point of starting their first biologic therapy. Both registers also aimed to recruit a cohort of patients receiving conventional synthetic DMARDs (csDMARDs) as comparator groups. In the UK, the British Society for Rheumatology Biologics Register for RA (BSRBR-RA) was designed to fulfil set recruitment targets and then stop recruiting when these targets were reached, rather than to capture data from all patients receiving biologic therapy 3 . This design differs from that of registers based in countries that adapted or developed existing patient registers (such as Sweden, Denmark and Switzerland). In the Antirheumatic Therapies in Sweden (ARTIS) register 5 , Danish National Registry for Biologic Therapy (DANBIO) 6 and Swiss Clinical Quality Management Programme for RA (SCQM-RA) 7 , captured biologics data is embedded within a larger national patient register that aims to capture outcome data on all patients with RA, regardless of whether they receive biologic therapies or not. Both approaches have their strengths and weaknesses and provide valuable sources of data on the effects of biologic therapies. Bespoke biologics registers have the advantage of deep data capture, particularly surrounding the occurrence and details of adverse events. However, due to the increased workload of capturing such data, these registers might not always capture data comprehensively. Conversely, external data sources, such as those available in Scandinavia, represent a unique opportunity to optimize data quality and reduce bias (for example, by using hospitalization data collected independently of the rheumatology register).
The large sample sizes, long follow-up periods and real-life populations included in biologics registers provide a contrast to in both the capture and the analysis of observational drug data when addressing questions around drug usage and effects in populations. We also highlight key lessons learnt by drawing examples from European registers during our discussion of potential future applications.
What is a biologics register?
The field of rheumatology has a long tradition of observational research 2 .
With the advent of biologic therapies for RA, many existing observational patient registers adapted their data collection to focus on outcomes following the exposure of patients to biologic therapies. Several countries also established new national biologics registers with the primary goal of studying treatment outcomes following the use of biologics (FIG. 1) .
In essence, a biologics register is an observational cohort study that captures detailed data on the exposure of patients to biologic therapies, such as details of Abstract | The beginning of the 21st century saw a biopharmaceutical revolution in the treatment of inflammatory rheumatic diseases, particularly rheumatoid arthritis. The fast-evolving use of biologic therapies highlighted the need to develop registers at national and international levels with the aim of collecting long-term data on patient outcomes. Over the past 15 years, many biologics registers have contributed a wealth of data and provided robust and reliable evidence on the use, effectiveness and safety of these therapies. The unavoidable challenges posed by the continuous introduction of new therapies, particularly with regard to understanding their long-term safety, highlights the importance of learning from experience with established biologic therapies. In this Perspectives article, the role of biologics registers in bridging the evidence gap between efficacy in clinical trials and real-world effectiveness is discussed, with a focus on methodological aspects of registers, their unique features and challenges and their role going forward. Lessons from biologics registers RCTs remain the benchmark for measuring the efficacy of new therapies; however, trials use stringent selection criteria, usually in an attempt to recruit a homogenous group of patients, which does not always represent the patients who will eventually receive the therapies being tested 9, 10 . Clinical trials are not usually sufficiently powered to study the risk of less common outcomes (such as serious infection), and as recruitment and follow-up often occur over a short period of time, latent effects (such as the risk of malignancy) might not be observed. Additionally, RCTs provide no information time from the Swiss SCQM-RA register, found that biologics were more frequently prescribed as monotherapy than in combination with csDMARDs to older patients with comorbidities, a lower BMI, a longer disease duration, higher disease activity and who had had a high number of previous biologics 7 . The study of register data over time has also provided insights into secular changes in the use of biologics; these therapies are now prescribed earlier in the course of treatment, following exposure to fewer csDMARDs and lower cumulative doses of glucocorticoids, to patients with milder disability than in previous years 12, 13 .
Effectiveness of biologic therapies.
If patient populations receiving biologics in the clinic differ from those included in RCTs, it follows that the expected response rates to therapy in these patients could also differ. In general, initial treatment responses are similar in registers to those observed in clinical trials 6, 14, 15 but, using data from registers, researchers can go beyond treatment response and analyse long-term on how clinical practice evolves over time. It is in these areas, therefore, that data from registers can complement data from clinical trials.
Biologics in clinical practice. Early reports from the German Rheumatoid Arthritis Observation of Biologic Therapy (RABBIT) 9 and Dutch Rheumatoid Arthritis Monitoring (DREAM) 10 registers showed that the majority of patients with RA receiving TNF inhibitors would not have been deemed eligible to participate in clinical trials. A proportion of these patients were too ill or disabled to participate, but there was also a proportion of patients whose disease was not active enough for them to be eligible. Data from the BSRBR-RA published in 2017 showed that patients with RA who started rituximab or tocilizumab as a first-line biologic had higher frequencies of important comorbidities (such as cancer or interstitial lung disease, conditions which often preclude participation in RCTs) than patients who started an anti-TNF agent as first-line therapy 11 . Another study, this treatment persistence 4, 16, 17 , an area that cannot be easily explored in clinical trials. According to data from the BSRBR, 50% of patients, on average, have discontinued their first biologic by 5 years, for reasons of either ineffectiveness or adverse events 16 . Register data can also be used to compare different biologic therapies. Data from the Danish DANBIO 6 and the Italian Grupo Italiano di Studio sulla Early Arthritis (GISEA) 18 registers suggest that infliximab was associated with the lowest rates of treatment response, disease remission and drug survival; the highest rates of treatment response and disease remission were observed with adalimumab and the longest drug survival rates with etanercept 6 . The lack of head-to-head trials of the best second-line treatments for RA also directed focus towards register data for the comparison of outcomes among patients switching between different treatment options. The majority of evidence from register data, including the Spanish Base de Datos de Productos Biológicos and tocilizumab [26] [27] [28] [29] [30] . Data on these newer biologics is either incorporated into existing registers or collected in newly developed registers.
In addition to providing data for describing and comparing biologic treatment responses, registers have also produced data that can help to describe the type of patients who achieve a good response with anti-TNF therapy. Factors identified as being associated with a good response to treatment include young age 6 , short disease duration 13 , good functional status at the start of therapy 6, 31, 32 and never smoking 31, [33] [34] [35] [36] . Furthermore, where studied, most registers have confirmed improved treatment responses among patients who start anti-TNF therapy alongside methotrexate, even in the setting of previous methotrexate failure 14, 16, 32, 37 . However, in all these examples, register data have shown that clinical data alone are not sufficient to predict which patients will have a good response to therapy, which has led to further biomarker studies in RA 38 . de la Sociedad Española de Reumatología (BIOBADASER) 19 and Swedish Stockholm TNFα Follow-up Registry (STURE) 20 , suggest that overall response rates are lower and drug-retention rates decrease in patients who switch to a second TNF inhibitor. Response to a second anti-TNF agent can differ according to the reason for failure of the first 21 . Data from the BSRBR 22 and SCQM-RA 23 registers reveal treatment with rituximab to be more effective than switching to an alternative anti-TNF agent in patients with RA who have persistently active disease despite treatment with a first anti-TNF agent, a finding supported by a non-register observational study 24 as well as by a large RCT 25 . These observations have formed a strong evidence base for decision-making in routine clinical practice. Although the majority of data collected to date has focused on TNF inhibitors, biologics registers are already providing information on the use of newer biologics, such as rituximab, abatacept 26, [39] [40] [41] [42] [43] . Further exploration of the data held within the German RABBIT register suggests that this observation is attributable both to a reduction in the number of patients at high risk of infection in the cohort, and to improvements in disease activity and reductions in steroid use among those patients who respond to therapy, thus reducing their overall infection risk 44 . Additionally, observational drug registers have enabled the study of the potential benefits of treatment with respect to safety outcomes, for example the association between use of anti-TNF agents and a reduced risk of cardiovascular events in patients with RA 45 . A number of registers have also published data on the observed risk of cancer in patients receiving Patient recruitment and missing data. Recruitment into a register can be active or passive. Active recruitment presents more challenges to the clinician, as it involves an additional step, which, when added to the environment of a busy clinic, means that not all of the patients who are eligible for the register might be recruited. To ensure the successful development, maintenance and consistent contribution to a register, it is important to have motivated physicians with a genuine interest in and belief in the value of clinical data collection for research. Often, such contribution is voluntary; however, in some countries it is a mandatory duty for clinicians to contribute a minimum amount of data (usually pre-specified on paper or electronic forms) to biologics registers. Such data include details of patient demographics and information about therapies, including any adverse events and reasons for discontinuation. However, in busy clinical settings, accurately completing even the minimum amount of information requested can pose a challenge, leading to incomplete forms being submitted and further adding to the administrative workload of the register. In this respect, site reimbursement for recruiting patients into a register might provide an incentive to clinicians. Passive recruitment is, in theory, simpler; however, a potential challenge is the disconnection between the person reporting the data and the person recording it as to why the data need to be captured. This, in turn, could risk incomplete or missing data, which are likely to be a mixture of missing covariate data and missing outcomes.
Actively encouraging those involved with registers to report the proportion of missing data, especially when studying key outcomes, is necessary and could prompt more complete data collection. Reducing the amount of missing data and improving the accuracy of the data collected is important for the quality of analyses and, consequently, for the findings and conclusions made. To improve data accuracy, adequate administrative input and encouragement of physicians or collectors are crucial.
Data collection and input. Securing reliable long-term funding to ensure register sustainability and having a robust, high quality and, ideally, web-based platform for data input, access and extraction represent important challenges for registers. The depth of data collected depends on the type of register and its design, which is often dictated by the research question(s) being biologics compared with patients receiving csDMARDs, and have not confirmed an increased risk of solid organ cancer or lymphoma [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] (see Supplementary information S1-S3 (tables)). Furthermore, biologics registers have enabled the study of outcomes in populations excluded from trials, such as patients with a history of cancer 52, 58 and the elderly 43 , and have revealed information about the risk of exposure to TNF inhibitors and other biologics during pregnancy 59, 60 . The provision of further insights into the real-world safety of biologic therapies represents one of the most valuable aspects of register data.
Methodological challenges
Developing and running a biologics register requires thorough logistical and methodological planning to ensure completeness of data recording and adequate administrative support. In the following sections, we address some of the more common methodological and analytical challenges presented by biologics registers, as summarized in studied. For example, some registers will collect data on the characteristics of patients and the disease, as well as treatment data and potential confounders. The actual process of data collection will depend on whether outcomes are reported or captured independently of the prescribing physician, or both.
Many registers use data linkage as a useful way of enriching source data. Data linkage enables further validation of events reported in source data, and ensures a more complete dataset, depending on the source of the linked data. Data linkage is particularly valuable when the linked data are in a mandatory national dataset, such as a national death or cancer register. The ability to validate the events captured through a linked route will depend upon the data capture methods of the independent data source.
Analytical challenges
Lack of randomization. The lack of randomization in the allocation of patients to treatments in routine clinical practice leads to confounding by indication, whereby observed outcomes might be related to the indication itself rather than to any exposure to the therapy. This lack of randomization, along with the absence of a control group and channelling bias, necessitate powered to measure the risk of very rare events, such as certain types of cancer. The insufficient power of individual registers to measure rare events, in particular, highlights one of the major benefits of using combined register data 47 .
Pooled versus parallel analysis. Possible solutions to the issue of weakly powered individual registers are data pooling and parallel analysis with meta-analysis. A considered approach is necessary when using this type of analytical technique to account for differences in register design and types of data collected, as well as differences in health care systems and geographical and population differences. Aside from inherent variations in the characteristics of patients (such as different genetic backgrounds), the presence of endemic diseases (such as tuberculosis or HIV), comorbid conditions and differences in access to biologics can affect disease severity at the onset of treatment and therefore the response of a patient to treatment. These variations pose challenges when studying drug safety or effectiveness. One way to address these variations is to take into account any potential register-caused modification of effect by using multi-level, stratified analyses with data from individual patients. If analysis of individual patient data is not feasible, meta-analysis of register data is often the next-preferred option. Beyond the type and nature of data collected across registers, ethical restrictions and patient consent might also be important obstacles to data sharing and pooled analysis. The recognition of these issues has resulted in the publication by EULAR of a series of points to consider when designing and establishing a biologics register 63 
Differences in recruitment patterns, data collected (items and definitions) and biologics prescription across registers is an important issue when pooling data for analysis 64 . To address these issues, the EULAR Study Group for Registers and Observational Studies (RODS) 64 specifically set out to compare patients starting treatment with biologics across Europe. This study, which involved 14 European biologics registers, acknowledged that differences in disease severity at the start of therapy do exist between countries, but also highlighted the lack of a common data model across Europe and the need for further work to harmonize data collection across registers 64 . Identifying a minimum core set of items for collection is therefore deemed to be appropriate and often advanced statistical methodology when analysing data, such as the use of propensity scores, econometric selection models or other approaches 61 . It should be acknowledged, though, that even with the use of advanced statistical methods, these biases might not be fully overcome. Confounding by indication often stems from the clinical reasons driving treatment choice as a result of physician and patient perceptions of disease severity, prognosis and treatment effect. However, other, 'extraneous' aspects, including socioeconomic factors, can also influence these decisions; countering these aspects requires appropriate epidemiological design and careful selection of control groups and analytical techniques 62 .
Time delays.
The delay between the entry of a drug into the market and the accumulation of sufficient outcome data for valid analyses into the drug's efficacy and safety needs to be considered. The analytical challenge in this situation relates both to the accumulated exposure of the patient to the drug and to the latency of adverse events relating to the drug. The issues of incomplete or missing data, missing patients (lost to follow-up) and the power of the study to detect rare events need to be carefully considered, as even the largest national registers might not be sufficiently Target population A biologics register should define the eligibility criteria for the population to be included in the register.
Data items to be collected pertaining to the treatment and the treated condition
Identifying a minimum core set of variables to be collected is important in ensuring data completeness and comparability across studies.
Data items to be collected pertaining to outcomes
Collection of data items pertaining to outcomes should be undertaken in a complete, robust and transparent manner.
Follow-up methods
A register should ensure similar follow-up methods are applied to the treatment-exposed and comparison cohorts.
Data collection process and data collectors
The process of data collection should be defined, achieving clarity on who will be providing and entering data, but also defining and testing data capture and entry.
Ethical and legal considerations of data handling and storage
It is important to ensure the security of patient-identifiable information and compliance with local legislation in relation to data handling and storage. useful in providing a common platform for data analysis across multiple registers. This premise forms the backbone of the EULAR Task Force on recommendations for the standardized content and structure of core data to facilitate patient care and observational research in RA.
The ability to standardize data collection across registers can lead to a better understanding of the reasons for heterogeneity in the results and conclusions between registers 8 , as well as improving the interpretation and comparison of drug class-specific and drug-specific risks 65 . Existing initiatives involving pooled data analysis 27, 29, 30 have provided insights into the influence of characteristics intrinsic to patients (such as age) and to the disease (such as antibody status), and to extrinsic factors (such as geographical influences and variations in treatment practice). The growing interest in pooling datasets for common data analysis represents a potential future application of biologics registers that would both increase their power and provide information on a diverse population of patients 64, 66 .
How to best use register data Many of the challenges and limitations discussed above will inevitably be present in any register, but this situation is acceptable as long as there is transparency as to the methodology and the limitations of the analysis 63 . Even discrepant findings can provide important information if the study design, analysis and data reporting are given careful consideration 8, 67 . The emphasis of the research questions and outcomes being examined in biologics registers is changing over time, shifting from focusing on disease behaviour, improving disease activity and decreasing disability to focus on treatment effectiveness in different diseases 68 and on individualizing treatment. For example, the question of which biologic to choose after a patient experiences an inadequate response or an adverse event with a TNF inhibitor 69 is now a common research agenda. Although the majority of biologics registers initially recruited only patients with RA, registers have been extended over time to include data on use of biologics in patients with other conditions (for example, ankylosing spondylitis or psoriatic arthritis), enabling the study of important outcomes in these disease areas 70, 71 . The knowledge gained from biologics registers over the past 15 years also provides a firm foundation for embarking on the collection Conclusions Biologics have had a groundbreaking effect on the treatment of RA, yet the future of RA and its treatment is not solely dependent on these drugs. The intensified treatment regimens and treat-to-target approaches that have emerged along with new therapies necessitate high levels of vigilance and carefully conducted studies to assess the safety, efficacy and effectiveness of these new therapies. The establishment of several national biologics registers aimed at understanding real-world effectiveness and safety of therapies beyond that observed in RCTs fills an important gap in the literature, enhancing our understanding of real-life aspects of these therapies and their effect on disease progression and long-term outcomes. The rich repository of data within these registers will have an ongoing role in complementing clinical trial data. Although challenges remain, with advanced methodologies and new technologies on the horizon the potential for novel uses of biologics registers remains promising.
of data for biosimilars, new classes of biologics and other advanced therapies. Several national rheumatology societies have already produced position papers on the use of biosimilars, recommending the registration of patients being treated with biosimilars into registers for surveillance of efficacy, safety and immunogenicity, following the strategy already ongoing for original biologics [72] [73] [74] .
Bridging the effectiveness-efficacy gap.
Reducing the discrepancies between effectiveness (in real-world conditions) and efficacy (in ideal circumstances) when evaluating new treatments would maximize the usefulness of information gathered by registers. Clinical trial data is useful for understanding efficacy of a therapy without the effect of confounding factors; however, efficacy across trial populations might not translate into equal effectiveness in patients in a real-world setting. With comparative effectiveness research becoming increasingly important, data from clinical trials are unlikely to provide answers to many important questions, in contrast to data from observational biologics registers 8 . Furthermore, biologics registers could be of value in studying subsets of the population that are not adequately studied in clinical trials, and in addressing the effectiveness, including the cost-effectiveness, of third-line and fourth-line biologics compared with the use of these drugs earlier in the treatment pathway.
Combined register-trial studies. With randomization being the only reliable method of controlling for confounding factors and enabling accurate comparison of treatment groups, clinical trials represent a strong foundation for evidence-based medicine 75 . However, running an adequately powered clinical trial incurs high costs, which, along with other limitations such as the select population of patients enrolled in RCTs (which might not represent an average patient seen in clinical practice), is an important problem. One possible solution would be to include a randomization module within a clinical register with unselected consecutive enrolment, thereby combining aspects of a prospective randomized trial with a large-scale clinical register 75 . Such an approach would potentially be an efficient and cost-effective future application of biologics registers, making it possible to obtain accurate answers to questions that data from clinical trials alone cannot provide.
